Antipsychotic-induced brain atrophy: Is lithium the answer in bipolar disorder?

Sagar Elangovan, Tarun Bastiampillai, Milanduth Kanigere, Sandip Kulkarni, Prashant Tibrewal

    Research output: Contribution to journalLetterpeer-review


    We note the recent debate piece (Bastiampillai et al., 2018) highlighting concerns about the potential implications of prescribing antipsychotic medication in paediatric populations, due to the potential risks of antipsychotic-induced brain atrophy. Worldwide antipsychotic medications are increasingly being prescribed for the maintenance treatment of bipolar affective disorder (BPAD) in preference to mood-stabilising medication like lithium. Lithium use is declining despite being the gold standard treatment for the maintenance phase of BPAD.

    Original languageEnglish
    Pages (from-to)925-926
    Number of pages2
    JournalAustralian and New Zealand Journal of Psychiatry
    Issue number9
    Publication statusPublished - 1 Sep 2019


    • prescribing antipsychotic medication
    • antipsychotic-induced brain atrophy
    • bipolar affective disorder (BPAD)
    • lithium
    • maintenace phase of BPAD


    Dive into the research topics of 'Antipsychotic-induced brain atrophy: Is lithium the answer in bipolar disorder?'. Together they form a unique fingerprint.

    Cite this